Top life sciences deals worldwide by value 2020

This statistic shows the leading announced life sciences deals worldwide during 2020 by total value. During that year, U.S.-based Bristol-Myers Squibb announced and completed the takeover of MyoKardia, a deal worth 13.1 billion U.S. dollars.

Leading life sciences deals based on value worldwide in 2020* (in billion U.S. dollars)

Bidder (Target)	Value in billion U.S. dollars.
AstraZeneca (Alexion)**	39
Gilead Sciences (Immunomedics)	21
Siemens Healthineers (Vaian Medical Systems)**	16.4
Bristol-Myers Squibb (MyoKardia)	13.1
Illumina (Grail)**	8
Johnson & Johnson (Momenta)	6.5
Gilead Sciences (Forty Seven)	4.9
Bayer (Asklepios BioPharmaceutical)**	4
Sanofi (Principia Biopharma)	3.7

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2021

More information

Region

Worldwide

Survey time period

2020

Supplementary notes

* Deals can also include M&As of parts/segments/divisions of companies.
Life sciences include: medicinal chemicals and botanical products; pharmaceutical preparations; in-vitro and in-vivo diagnostics; biotechnology, biological products, except diagnostic substances; pharmaceutical wholesale; medical devices and diagnostics; plant sciences.
** Pending as of publication date.

Open this statistic in...

Spanish

Citation formats